Author pages are created from data sourced from our academic publisher partnerships and public sources.
Share This Author
Phase I imaging study of the HER3 antibody RG7116 using 89Zr-RG7116-PET in patients with metastatic or locally advanced HER3-positive solid tumors.
In vivo biodistribution and tumor targeting characteristics of RG7116 are determined by means of immunoPET using 89Zr-RG7116 and tracer uptake in organs of interest and tumor lesions was quantified as standardized uptake value (SUV) and tumor-to-background ratios (TBR).
315 ImmunoPET and Biodistribution with Human Epidermal Growth Factor Receptor 3 Targeting Radiolabeled Antibody 89Zr-GE-huMAb-HER3
Abstract A85: Preclinical evaluation of the radiolabeled bispecific T-cell engager 89Zr-AMG 211 targeting CEA-positive tumors
This study showed dose-dependent CEA-specific targeting of 89Zr-AMG 211 in LS174T bearing mice with the highest uptake 3 h after injection and a prolonged imageable tumor retention up to 48 h, and showed similar CEA binding as unlabeled AMG 211.
Abstract 5307: VEGF downregulation by HSP90 inhibitor NVP-AUY922 visualized with89Zr-bevacizumab PET in triple negative breast cancer (TNBC)
NPV-AUY922 downregulates VEGF in a TNBC mouse model, and can therefore potentially serve as biomarker for early HSP90 inhibition effect in TNBC.
MAPK pathway activity plays a key role in programmed death ligand-1 expression of EGFR wild-type non-small cell lung adenocarcinoma cells
Tumor-specific uptake of fluorescent bevacizumab-IRDye 800 CW microdosing in patients with primary breast cancer
535 Tumor targeting and tissue distribution of solitomab (AMG 110; anti-EpCAM BiTE®) in human EpCAM-positive tumor bearing mice
Imaging human pancreatic tumor xenografts with 89Zr-labeled anti-mesothelin antibody
89Zr-AMA tumor uptake is antigen-specific in MSLN-expressing tumors and can be translated to the clinic for serial non-invasive PET imaging.
89Zr-lumretuzumab PET imaging before and during HER3 antibody lumretuzumab treatment of solid tumor patients.
A PET imaging study with 89Zr-lumretuzumab was performed to demonstrate tumor targeting and support dose selection by evaluating the dose required for target saturation in patients with HER3-positive solid tumors.